Why Collegium Pharmaceutical Stock Is Crushing It Today [The Motley Fool]
Collegium Pharmaceutical, Inc. (COLL)
Last collegium pharmaceutical, inc. earnings: 2/27 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.collegiumpharma.com
Company Research
Source: The Motley Fool
Why Collegium Pharmaceutical Stock Is Crushing It Today Investors are excited about the drugmaker's big formulary wins for its abuse-deterrent opioid drug. Shares of Collegium Pharmaceutical ( NASDAQ:COLL ) were soaring 33.7% higher as of 11:12 a.m. EST on Thursday. This big jump came following the small drugmaker's third-quarter update after the market closed on Wednesday. Collegium missed Wall Street estimates on both its top and bottom lines. However, the company announced exclusive formulary deals for its abuse-deterrent Xtampza ER opioid painkiller that will cover more than 35 million lives beginning in January 2020. Collegium's huge gain today demonstrates why investing in stocks is all about the future rather than the past. No one cared about the company missing revenue and earnings estimates when its fortunes are about to get much brighter. Xtampza ER generated $26.5 million in net product revenue in Q3, up 56% year over year. But that sales level was achieved with the drug o
Show less
Read more
Impact Snapshot
Event Time:
COLL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
COLL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
COLL alerts
High impacting Collegium Pharmaceutical, Inc. news events
Weekly update
A roundup of the hottest topics
COLL
News
- Collegium Pharmaceutical, Inc. (NASDAQ: COLL) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.MarketBeat
- Is Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) ROE Of 25% Impressive? [Yahoo! Finance]Yahoo! Finance
- Collegium Pharmaceutical, Inc. Announces Redemption of Outstanding 2.625% Convertible Senior Notes Due 2026 [Yahoo! Finance]Yahoo! Finance
- Collegium Pharmaceutical, Inc. (NASDAQ: COLL) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $40.00 price target on the stock.MarketBeat
- Collegium Pharmaceutical, Inc. Announces Redemption of Outstanding 2.625% Convertible Senior Notes Due 2026GlobeNewswire
COLL
Earnings
- 2/22/24 - Beat
COLL
Sec Filings
- 4/11/24 - Form 8-K
- 4/5/24 - Form ARS
- 4/5/24 - Form DEFA14A
- COLL's page on the SEC website